Review says GLP-1 obesity trials never used validated nausea instruments

The wire

1. 01A narrative review in Diabetes, Obesity & Metabolism traced nausea measurement across the liraglutide SCALE, semaglutide STEP and tirzepatide SURMOUNT programmes and found no validated symptom-specific patient-reported outcome instrument was used.
2. 02The authors argue this measurement gap helps explain why real-world persistence with GLP-1 receptor agonists falls short of trial-reported tolerability, a mismatch prescribers and telehealth operators see in discontinuation rates.
3. 03The paper is an argument rather than new data; it outlines what a fit-for-purpose metabolic nausea instrument would need to capture but no such tool is validated yet.

From the source

How Well Are We Measuring Nausea? A Narrative Review of Patient-Reported Outcome Gaps in GLP-1 Receptor Agonist Obesity Trials

Diabetes, obesity & metabolism · 2026 Oct 22 · Oria L, Darkhabani M et al.